Targeted Agents in Treatment of Neuroendocrine Tumors of Pancreas

  • Ilias N Karampelas Oncology Department, Athens Medical Group. Athens, Greece
  • Kostas N Syrigos Oncology Unit, Third Department of Medicine, University of Athens. Athens, Greece
  • Muhammad Wasif Saif Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine. Boston, MA, USA
Keywords: Diabetes Mellitus, Hyperinsulinism, Neoplasms, Pancreatic Neoplasms


Neuroendocrine tumors (NET) of the pancreas are uncommon neoplasms that arise from the pancreatic islet cells. Surgical resections are being tested, as well as multiple chemotherapy agents. Current treatment options for nonresectable disease include somatostatin analogs and chemotherapy. New therapies focus on specific molecular targets such as sunitinib, angiogenesis inhibitor, that target vascular endothelial growth factor receptor (VEGFR) and other growth factor receptors and everolimus, an inhibitor of the mammalian target of rapamycin. Functionally based medical therapies for NET include somatostatin analogs to control symptoms. The 2014 annual meeting of American Society of Clinical Oncology (ASCO) brought us new insights into the management of pancreatic neuroendocrine tumors. The focus of this review will serve to highlight specific Abstracts (#e15160 and #e15161), that shed light on new therapeutic options that help target the unique pathways of this malignancies.

Image: Athens Medical Group logo. Athens, Greece.


Download data is not yet available.


KjellÖberg, Daniel Castellano. Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer and Metastasis Reviews, March 2011, Volume 30, Issue 1 Supplement, 3-7

Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008; 19: 1727-1733.

Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, et al. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26:3063-3072. [PMID:18565894]

Shah MH, Ito T, Lombard-Bohas C, Wolin EM, Van Cutsem E, Sachs C, Winkler RE, et al. Everolimus in patients with advanced pancreatic neuroendocrine tumors: Updated results of a randomized, doubleblind, placebo-controlled multicenter phase III trial (RADIANT-3). J Clin Oncol. 2011; 29(Suppl. 4):158.

Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999; 17(2):600. [PMID:10080605]

Raymond E, Dahan L, Raoul J-L, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:501-13.

Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, et al. Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009; 27(28):4656. [PMID:19704057]

Arnold R, Wittenberg M, Rinke A, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress TM, et al. Placebo controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results on long-term survival. ASCO 2013 Abstract No: # 4030.

Bajetta E, Catena L, Fazio N, Pusceddu S, Biondani P, Blanco G, Ricci S, et al. Everolimus in combination with octreotide LAR as the first-line treatment for advanced neuroendocrine tumors: A phase II trial of the I.T.M.O. (Italian Trials in Medical Oncology) group. ASCO 2013 Abstract No: #4136.

Bajetta E, Catena L, Pusceddu S, Spada F, Fazio N, Blanco G, Ricci S, et al. Updated overall survival and time to progression results in NETs treated with everolimus combination with octreotide LAR as first-line treatment. J Clin Oncol. 32, 2014 (suppl; abstr#e15160).

Geboes KP, Laurent S, Verroken C, Cesmeli E, Lambert B, Smeets P, Vanlander A, et al. Durable disease control with sunitinib and everolimus in well-differentiated neuroendocrine tumors of the pancreas with a high ki67 index. J Clin Oncol. 32, 2014 (suppl; abstr#e15161).

Kulke MH. Systemic therapy for advanced pancreatic neuroendocrine tumors. Semin Oncol. 2013; 40(1): 75-83. [PMID:23391115]

Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005; 8: 299-309. [PMID:16226705]

Athens Medical Group logo. Athens, Greece
How to Cite
KarampelasI., SyrigosK., & SaifM. (2014). Targeted Agents in Treatment of Neuroendocrine Tumors of Pancreas. JOP. Journal of the Pancreas, 15(4), 351-353.
Highlights from the “50th ASCO Annual Meeting 2014”. Chicago, IL, USA. May 30 - June 3, 2014